A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial
Mette Bjørndal Axelsen, Iris Eshed, Kim Hørslev-Petersen, Kristian Stengaard-Pedersen, Merete Lund Hetland, Jakob Møller, Peter Junker, Jan Pødenphant, Annette Schlemmer, Torkell Ellingsen, Palle Ahlquist, Hanne Lindegaard, Asta Linauskas, Mette Yde Dam, Ib Hansen, Hans Christian Horn, Christian Gytz Ammitzbøll, Anette Jørgensen, Sophine B Krintel, Johnny Raun, Niels S Krogh, Julia Sidenius Johansen, Mikkel Østergaard, OPERA study group
Annals of the Rheumatic Diseases May 2015, 74 (5) 867-875; DOI: 10.1136/annrheumdis-2013-204537